Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and its impact on allogeneic hematopoietic cell transplantation donor selection: A summary of the SBTMO/ABHI joint session at the 2025 SBTMO annual meeting

Authors

  • Alberto Cardoso Martins Lima Universidade Federal do Paraná – Complexo Hospital de Clínicas – Curitiba (PR), Brazil|Associação Fundo de Incentivo à Pesquisa – Instituto de Imunogenética – São Paulo (SP), Brazil. https://orcid.org/0000-0002-7248-7060
  • Antonio Martin Jimenez-Jimenez University of Miami – Miller School of Medicine – Sylvester Comprehensive Cancer Center – Miami (FL), USA. https://orcid.org/0000-0003-2817-6836
  • Celso Arrais Rodrigues da Silva Universidade Federal de São Paulo – Programa de Pós-Graduação: Medicina (Hematologia e Oncologia) – São Paulo (SP), Brazil|Rede DASA – Hospital Nove de Julho – São Paulo (SP), Brazil. https://orcid.org/0000-0002-6395-6849
  • Adriana Seber Universidade Federal de São Paulo – Instituto de Oncologia Pediátrica – São Paulo (SP), Brazil|Rede DASA – Hospital Samaritano – São Paulo (SP), Brazil|Grupo de Apoio ao Adolescente e à Criança com Câncer – Instituto de Oncologia Pediátrica – São Paulo (SP), Brazil. https://orcid.org/0000-0003-4578-9423
  • Raquel Aparecida Salustriano Fabreti de Oliveira Imunolab – Laboratório de Histocompatibilidade – Belo Horizonte (MG), Brazil|Faculdade de Ciências Médicas de Minas Gerais – Programa de Pós-Graduação em Ciências da Saúde – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0001-9128-0666
  • Margareth Afonso Torres Hospital Israelita Albert Einstein – São Paulo (SP), Brazil. https://orcid.org/0000-0002-6334-6215
  • Carmem Bonfim Duke University – Pediatric Transplant and Cellular Therapy Division – Durham (NC), USA. https://orcid.org/0000-0003-0343-2610

DOI:

https://doi.org/10.46765/2675-374X.2025v7n1e314

Keywords:

Donor selection, Hematopoietic cell transplantation, Post-transplant cyclophosphamide, Alternative donors, Virtual crossmatch, Donor-specific HLA antibodies

Abstract

This brief communication summarizes the joint session of the Brazilian Cellular Therapy and Bone Marrow Transplantation Society (SBTMO) and the Brazilian Histocompatibility and Immunogenetics Association (ABHI), held during the 2025 SBTMO Annual Meeting. The joint session focused on how post-transplant cyclophosphamide (PTCy) is redefining donor selection in contemporary allogeneic hematopoietic cell transplantation (HCT). In three lectures with experts in the field, several topics concerning PTCy were addressed, including the effectiveness of PTCy in overcoming the HLA barrier, the increased use of mismatched unrelated donors (MMUD) under PTCy, which significantly broadens HCT access for underserved ethnic minorities, and strategies for reducing the dose of PTCy. The impact of donor-specific HLA antibodies in allogeneic HCT, the importance of HLA serotypes (associated antigens) in improving the accuracy of virtual crossmatch during MMUD searches, and the utility of novel bioinformatics tools to enhance serotype evaluation for MMUD selection under PTCy were also discussed. Additionally, the present report outlines the discussions among the speakers, session chairs, and audience members.

References

1. Chowdhury AS, Maiers M, Spellman SR, Deshpande T, Bolon YT, Devine SM. Existence of HLA mismatched unrelated donors closes the gap in donor availability regardless of recipient ancestry. Transplant Cell Ther. 2023;29(11):686.e1-686.e8. https://doi.org/10.1016/j.jtct.2023.08.014 DOI: https://doi.org/10.1016/j.jtct.2023.08.014

2. Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolaños-Meade J, Abboud R, et al. Post-transplant cyclophosphamidebased graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol. 2024;42(28):3277-86. https://doi.org/10.1200/JCO.24.00184 DOI: https://doi.org/10.1200/JCO.24.00184

3. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021 Jun 20;39(18):1971-82. https://doi.org/10.1200/JCO.20.03502 DOI: https://doi.org/10.1200/JCO.20.03502

4. Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, et al. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation. J Clin Oncol. 2025 Jun 16;JCO2500856. https://doi.org/10.1200/JCO-25-00856 DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.6503

5. Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, et al. Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP/CIBMTR. Transplant Cell Ther. 2025 Jul 5;31(12). https://doi.org/10.1016/j.jtct.2025.07.004 DOI: https://doi.org/10.1016/j.jtct.2025.07.004

6. Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019 Sep 12;134(11):892-9. https://doi.org/10.1182/blood.2019000487 DOI: https://doi.org/10.1182/blood.2019000487

7. Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022 Jun 14;6(11):3378-85. https://doi.org/10.1182/bloodadvances.2021005847 DOI: https://doi.org/10.1182/bloodadvances.2021005847

8. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338-48. https://doi.org/10.1056/NEJMoa2215943 DOI: https://doi.org/10.1056/NEJMoa2215943

9. Araujo TFN de, Rocha LP dos S, Oliveira CF de, Ferreira C de F de M, Souza BA de, Puls ML, et al. Impact of reduced-dose of post-transplantation cyclophosphamide (PTCy) in HLA-identical and haploidentical hematopoietic stem cell transplantation: a retrospective analysis. Blood. 2024 Nov 5;144 (Suppl 1):7324. https://doi.org/10.1182/blood-2024-211512 DOI: https://doi.org/10.1182/blood-2024-211512

10. Xie Y, Parekh J, Tang Z, Wu D, Wu X. Donor-specific antibodies and primary graft failure in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther. 2021 Aug;27(8):687.e1-687.e7. https://doi.org/10.1016/j.jtct.2021.04.030 DOI: https://doi.org/10.1016/j.jtct.2021.04.030

11. Huang Y, Luo C, Wu G, Huang X, Ding Y, Huang Z, et al. Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2023 May;58(5):544-51. https://doi.org/10.1038/s41409-023-01932-6 DOI: https://doi.org/10.1038/s41409-023-01932-6

12. Sullivan HC, Jaramillo A, Gaitonde S, Murphey C, Pandey S, Liu C, et al. Virtual crossmatching: principles, practices, and the path forward – an American Society for Histocompatibility and Immunogenetics/College of American Pathologists collaborative. Am J Transplant. 2025 Jun 21;25(10). https://doi.org/10.1016/j.ajt.2025.06.018 DOI: https://doi.org/10.1016/j.ajt.2025.06.018

13. da Silva JS, Visentainer JEL, Fabreti-Oliveira RA, de Souza FCB, Silva MNP, da Costa Sena A, et al. Common, intermediate and well-documented HLA alleles in the Brazilian population: an analysis of the Brazilian Bone Marrow Donor Registry (REDOME). HLA. 2025 Feb;105(2):e70051. https://doi.org/10.1111/tan.70051 DOI: https://doi.org/10.1111/tan.70051

14. Holdsworth R, Hurley CK, Marsh SGE, Lau M, Noreen HJ, Kempenich JH, et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens. 2009 Feb;73(2):95-170. https://doi.org/10.1111/j.1399-0039.2008.01183.x DOI: https://doi.org/10.1111/j.1399-0039.2008.01183.x

15. Osoegawa K, Marsh SGE, Holdsworth R, Heidt S, Fischer G, Murphey C, et al. A new strategy for systematically classifying HLA alleles into serological specificities. HLA. 2022 Sep;100(3):193-231. https://doi.org/10.1111/tan.14662 DOI: https://doi.org/10.1111/tan.14662

16. Osoegawa K, Yim K, Jeracki M, Nguyen TN, Wang L, Cho A, et al. A new strategy for systematically classifying HLA alleles into serological specificities: update and refinement. HLA. 2024;104(4):e15702. https://doi.org/10.1111/tan.15702 DOI: https://doi.org/10.1111/tan.15702

17. Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022 Mar 10;139(10):1452-68. https://doi.org/10.1182/blood.2021013443 DOI: https://doi.org/10.1182/blood.2021013443

18. Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020 Jan;55(1):12-24. https://doi.org/10.1038/s41409-019-0499-z DOI: https://doi.org/10.1038/s41409-019-0499-z

19. Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, et al. Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the Acute Leukemia Working Party of the EBMT. HemaSphere. 2023 Jul;7(7):e920. https://doi.org/10.1097/HS9.0000000000000920 DOI: https://doi.org/10.1097/HS9.0000000000000920

20. Kassim AA, de la Fuente J, Nur E, Wilkerson KL, Alahmari AD, Seber A, et al. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. Blood. 2024 Jun 20;143(25):2654-65. https://doi.org/10.1182/blood.2023023301 DOI: https://doi.org/10.1182/blood.2023023301

21. Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, et al. ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies. Transplant Cell Ther. 2024 Dec;30(12):1139-54. https://doi.org/10.1016/j.jtct.2024.09.005 DOI: https://doi.org/10.1016/j.jtct.2024.09.005

22. Wiebe C, Gareau AJ, Pochinco D, Gibson IW, Ho J, Birk PE, et al. Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival. Am J Transplant. 2017 Mar;17(3):703-11.https://doi.org/10.1111/ajt.14015 DOI: https://doi.org/10.1111/ajt.14015

23. Bettinotti MP. Evolution of HLA testing for hematopoietic stem cell transplantation: importance of the candidate’s antibody profile for donor selection. Hum Immunol. 2022;83(10):721-9. https://doi.org/10.1016/j.humimm.2022.04.012 DOI: https://doi.org/10.1016/j.humimm.2022.04.012

24. Eyrich M, Schulze H. HLA matching in pediatric stem cell transplantation. Transfus Med Hemother. 2019;46(5):348-55. https://doi.org/10.1159/000502422 DOI: https://doi.org/10.1159/000502422

25. Doherty EE, Krance RA. Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia? Hematology Am Soc Hematol Educ Program. 2023 Dec 8; 2023(1):171-4. https://doi.org/10.1182/hematology.2023000522 DOI: https://doi.org/10.1182/hematology.2023000522

26. Arrieta-Bolaños E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, et al. Human leukocyte antigen mismatching and survival in contemporary hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2024;42(28):3287-99. https://doi.org/10.1200/JCO.24.00582 DOI: https://doi.org/10.1200/JCO.24.00582

27. Crivello P, Arrieta-Bolaños E, He M, Wang T, Fingerson S, Gadalla SM, et al. Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation. J Clin Oncol. 2023 May 1;41(13):2416-27. https://doi.org/10.1200/JCO.22.01229 DOI: https://doi.org/10.1200/JCO.22.01229

Downloads

Published

03/11/2026

How to Cite

Lima, A. C. M., Jimenez-Jimenez, A. M., Silva, C. A. R. da, Seber, A., Oliveira, R. A. S. F. de, Torres, M. A., & Bonfim, C. (2026). Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and its impact on allogeneic hematopoietic cell transplantation donor selection: A summary of the SBTMO/ABHI joint session at the 2025 SBTMO annual meeting. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 7(1). https://doi.org/10.46765/2675-374X.2025v7n1e314

Issue

Vol. 7 No. 1 (2026): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Short communication

License

Copyright (c) 2026 Alberto Cardoso Martins Lima, Antonio Martin Jimenez-Jimenez, Celso Arrais Rodrigues da Silva, Adriana Seber, Raquel Aparecida Salustriano Fabreti de Oliveira, Margareth Afonso Torres, Carmem Bonfim

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.